Overview

Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy

Status:
Active, not recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
1. Establish a predictive model for the efficacy of immune checkpoint inhibitors (ICI) in Chinese patients with biliary tract cancers. By analyzing the dynamic changes of circulating tumor DNA (ctDNA) and other clinical and pathological features before and after ICI treatment in a cohort of patients with biliary tract tumors, a predictive model can be established to evaluate the efficacy of ICI treatment in the early stages or even before treatment, serving as a reliable tool for selecting patients who are likely to benefit from ICI treatment. 2. Investigate the clinical features of populations that benefit from different immune combination therapies. By comparing the differences and enrichment of mutations between patients receiving different treatment regimens, and if patients have sufficient pre-treatment tissue, further comparisons of differentially expressed genes and pathways may be made.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
Geneplus-Beijing Co. Ltd.
Treatments:
Immune Checkpoint Inhibitors